MA-EXAGRID
24.1.2022 14:02:12 CET | Business Wire | Press release
ExaGrid ® , the industry’s only Tiered Backup Storage solution, today announced that a newly published ESG technical review, ExaGrid with Commvault: Maximum Deduplication Savings with Easy Management authored by Kerry Dolan, Sr. IT Validation Analyst and Craig Ledo, IT Validation Analyst, documents ESG’s validation of ExaGrid testing that demonstrated both the capacity savings and ease of use available from a combined ExaGrid and Commvault backup solution. The data deduplication from Commvault can remain turned on and ExaGrid furthers the Commvault deduplication by a factor of 3:1.
From the ESG report:
“It is well known that both ExaGrid and Commvault offer backup solutions that are easy to use and can help you to store data more efficiently with deduplication. What may be less well known is that a combined ExaGrid and Commvault solution can achieve even greater deduplication: up to 20:1 in many cases. A 20x reduction in backup storage costs can be a significant boost to any budget.
ESG validated that:
- The combined ExaGrid/Commvault solution reduced a 123TB backup data set that included 15 days of file data, VMware VMs, and SQL database backups down to 8.66TB, a 14:1 reduction, in a realistic yet intentionally conservative test environment.
- Deploying and managing the combined solution was simple, intuitive, and fast.”
ExaGrid Tiered Backup Storage requires close integration between the backup software and the backup storage. Together, Commvault and ExaGrid provide a cost-effective backup solution that scales to meet the needs of demanding enterprise environments. ExaGrid improves the storage economics of Commvault environments by working with Commvault deduplication on to provide up to 20:1 reduction in storage consumption – a 3X storage savings over using Commvault deduplication alone. This combination dramatically lowers the cost of onsite and offsite backup storage.
Commvault deduplicated data can be sent to ExaGrid appliances for further deduplication. ExaGrid takes the average 5:1 Commvault deduplication ratio up to 15:1 which reduces the storage footprint by 300%. This greatly reduces the cost of the backup storage while allowing no change to the current Commvault configuration since the Commvault deduplication can remain on. In this example, ExaGrid can replicate the 15:1 deduplicated data to a second site for offsite long-term retention and disaster recovery. The additional deduplication saves WAN bandwidth in addition to saving storage at both sites.
“ExaGrid continues to innovate to optimize integration with the backup applications we support, providing our customers with unique benefits for the backup applications that they use. We have been able to further deduplicate Commvault’s deduped data for some time now to maximize storage savings, and this new report highlights how well this actually works, all without requiring current Commvault users to make changes to their configuration,” said Bill Andrews, President and CEO of ExaGrid. “We hope that current Commvault users and those who are planning to use Commvault will take a look at this report and consider the storage savings that ExaGrid can bring to their backup environment. Separately, ExaGrid can greatly improve Commvault backup and restore performance if Commvault deduplication is turned off. In this case, ExaGrid provides the same storage savings but with greatly improved backup and restore performance. ExaGrid gives Commvault customers the option to keep Commvault deduplication turned on, or for improved performance, turned off.”
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom